Completed PHASE1 INTERVENTIONAL 6-arm NCT00741169

TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.

Phase I, Open-label, 3-way Crossover Trial in Healthy Volunteers to Determine the Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.

Sponsor: Tibotec Pharmaceuticals, Ireland

Conditions HCV Hepatitis C Pharmacokinetics Rifampin Tuberculosis

Interventions Rifampin TMC435350 TMC435350+rifampin

Updated 6 times since 2017 Last updated: Apr 17, 2013 Started: Jun 30, 2008 Primary completion: Dec 31, 2008 Completion: Dec 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on HCV and Hepatitis C, this trial is completed. The trial is conducted by Tibotec Pharmaceuticals, Ireland and has accumulated 6 data snapshots since 2008. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tibotec Pharmaceuticals, Ireland

Data source: Tibotec Pharmaceuticals, Ireland

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.